Tien-Ying Fan1, Lian Zhang, Wenzhi Chen, Yinjiang Liu, Min He, Xiu Huang, Franco Orsi, Zhibiao Wang. 1. State Key Laboratory of Ultrasound Engineering in Medicine, Department of Biomedical Engineering, Chongqing Medical University, Clinical Center of Tumor Therapy, 2nd Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Abstract
PURPOSE: To test the feasibility of MRI-guided high intensity focused ultrasound ablation for adenomyosis. MATERIALS AND METHODS: Patients with symptomatic adenomyosis were treated with MRI-guided high intensity focused ultrasound (MRIgHIFU). Under conscious sedation, MRIgHIFU was performed by a clinical MRI-compatible focused ultrasound tumour therapeutic system (JM15100, Haifu® Technology Co. Ltd., Chongqing, China) which is combined with a 1.5 T MRI system (Magnetom Symphony, Siemens Healthcare, Erlangen, Germany). MRI was used to calculate the volume of the uterus and lesion. Non-perfused volume of the targeted lesions was evaluated immediately after MRIgHIFU. Patient symptoms were assessed using symptom severity score (SSS) and uterine fibroids symptoms and quality of life questionnaire (UFS-QOL). RESULTS: Ten patients with mean age of 40.3±4 years with an average lesion size of 56.9±12.7 mm in diameter were treated. Non-perfused volume and the percentage of non-perfused volume obtained from contrast-enhanced T1 Magnetic resonance images immediately post-treatment were 66.6±49.4 cm3 and 62.5±21.6%, respectively. The mean SSS and UFS-QOL showed significant improvements of 25%, 16% and 25% at 3, 6 and 12 months follow up, respectively, to pre-treatment scores. No serious complications were observed. CONCLUSION: Based on the results from this study, MRIgHIFU treatment appears to be a safe and feasible modality to ablate adenomyosis lesion and alleviate its symptoms.
PURPOSE: To test the feasibility of MRI-guided high intensity focused ultrasound ablation for adenomyosis. MATERIALS AND METHODS:Patients with symptomatic adenomyosis were treated with MRI-guided high intensity focused ultrasound (MRIgHIFU). Under conscious sedation, MRIgHIFU was performed by a clinical MRI-compatible focused ultrasound tumour therapeutic system (JM15100, Haifu® Technology Co. Ltd., Chongqing, China) which is combined with a 1.5 T MRI system (Magnetom Symphony, Siemens Healthcare, Erlangen, Germany). MRI was used to calculate the volume of the uterus and lesion. Non-perfused volume of the targeted lesions was evaluated immediately after MRIgHIFU. Patient symptoms were assessed using symptom severity score (SSS) and uterine fibroids symptoms and quality of life questionnaire (UFS-QOL). RESULTS: Ten patients with mean age of 40.3±4 years with an average lesion size of 56.9±12.7 mm in diameter were treated. Non-perfused volume and the percentage of non-perfused volume obtained from contrast-enhanced T1 Magnetic resonance images immediately post-treatment were 66.6±49.4 cm3 and 62.5±21.6%, respectively. The mean SSS and UFS-QOL showed significant improvements of 25%, 16% and 25% at 3, 6 and 12 months follow up, respectively, to pre-treatment scores. No serious complications were observed. CONCLUSION: Based on the results from this study, MRIgHIFU treatment appears to be a safe and feasible modality to ablate adenomyosis lesion and alleviate its symptoms.
Authors: Fabiana Ferrari; Francesco Arrigoni; Anna Miccoli; Sara Mascaretti; Eva Fascetti; Giulio Mascaretti; Antonio Barile; Carlo Masciocchi Journal: Radiol Med Date: 2015-09-09 Impact factor: 3.469
Authors: M Xia; Z Jing; H Zhi-Yu; C Jian-Ming; Z Hong-Yu; X Rui-Fang; Y Yu; H Yan-Li; D Bao-Wei Journal: Br J Radiol Date: 2014-06-20 Impact factor: 3.039
Authors: Marissa J Harmsen; Caroline F C Wong; Velja Mijatovic; Arjan W Griffioen; Freek Groenman; Wouter J K Hehenkamp; Judith A F Huirne Journal: Hum Reprod Update Date: 2019-09-11 Impact factor: 15.610
Authors: Lifei Zhu; Ari Partanen; Michael R Talcott; H Michael Gach; Suellen C Greco; Lauren E Henke; Jessika A Contreras; Imran Zoberi; Dennis E Hallahan; Hong Chen; Michael B Altman Journal: Int J Hyperthermia Date: 2019 Impact factor: 3.914